We are live on ! Find out more
CALA

Calithera Biosciences, Inc

Delisted

CALA was delisted on the 1st of February, 2023.

100 hedge funds and large institutions have $142M invested in Calithera Biosciences, Inc in 2018 Q1 according to their latest regulatory filings, with 13 funds opening new positions, 36 increasing their positions, 31 reducing their positions, and 23 closing their positions.

New
Increased
Maintained
Reduced
Closed

16% more repeat investments, than reductions

Existing positions increased: 36 | Existing positions reduced: 31

11% less funds holding

Funds holding: 112100 (-12)

31% less capital invested

Capital invested by funds: $204M → $142M (-$62.4M)

42% less call options, than puts

Call options by funds: $536K | Put options by funds: $923K

43% less first-time investments, than exits

New positions opened: 13 | Existing positions closed: 23

Holders
100
Holders Change
-12
Holders Change %
-10.71%
% of All Funds
2.29%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
13
Increased
36
Reduced
31
Closed
23
Calls
$536K
Puts
$923K
Net Calls
-$387K
Net Calls Change
-$300K
Name Holding Trade Value Shares
Change
Change in
Stake
Charles Schwab
26
Charles Schwab
California
$794K +$107K +685 +12%
SCA
27
Secor Capital Advisors
New York
$577K +$484K +3,102 +210%
VEA
28
Virtus ETF Advisers
New York
$559K +$367K +2,353 +113%
FSA
29
Franklin Street Advisors
North Carolina
$545K +$242K +1,550 +56%
Allianz Asset Management
30
Allianz Asset Management
Germany
$516K +$18.2K +117 +3%
GCP
31
GSA Capital Partners
United Kingdom
$512K +$634K +4,063 New
AIMCA
32
Alberta Investment Management Corp (AIMCo)
Alberta, Canada
$466K +$232K +1,485 +67%
Citadel Advisors
33
Citadel Advisors
Florida
$464K -$6.29M -40,312 -92%
Acadian Asset Management
34
Acadian Asset Management
Massachusetts
$460K +$400K +2,568 +237%
Jennison Associates
35
Jennison Associates
New York
$456K -$42.7K -274 -7%
CAM
36
ClariVest Asset Management
California
$445K +$98.2K +630 +22%
AIM
37
Assured Investment Management
New York
$436K +$540K +3,460 New
Morgan Stanley
38
Morgan Stanley
New York
$434K -$21.1K -135 -4%
Squarepoint
39
Squarepoint
New York
$429K -$35.9K -230 -6%
Wells Fargo
40
Wells Fargo
California
$414K +$27.1K +174 +6%
Bank of America
41
Bank of America
North Carolina
$397K +$302K +1,937 +160%
T. Rowe Price Associates
42
T. Rowe Price Associates
Maryland
$387K +$100K +643 +26%
TI
43
Trexquant Investment
Connecticut
$378K +$93.6K +600 +25%
CM
44
Crestline Management
Texas
$378K +$468K +3,004 New
Jacobs Levy Equity Management
45
Jacobs Levy Equity Management
New Jersey
$368K +$311K +1,995 +215%
USAA
46
United Services Automobile Association
Texas
$350K +$41.2K +264 +10%
PAM
47
Panagora Asset Management
Massachusetts
$319K -$554K -3,551 -58%
AA
48
ALPS Advisors
Colorado
$300K +$64.4K +413 +21%
California State Teachers Retirement System (CalSTRS)
49
California State Teachers Retirement System (CalSTRS)
California
$298K -$7.33K -47 -2%
Swiss National Bank
50
Swiss National Bank
Switzerland
$285K

CALA Hedge Fund Activity: Q1 2018 in Review

100 of the 4,363 institutional investors tracked by Wall St. Rank reported a position in Calithera Biosciences, Inc (CALA) for Q1 2018, worth a combined $142M — down 31% from $204M a quarter earlier.

Sellers outnumbered buyers: 23 funds closed out of CALA and 13 opened new positions — a net loss of 10 holders — while 31 trimmed existing stakes and 36 added.

The largest buyer was Federated Hermes, opening a new position worth an estimated $11.1M. The largest seller was Viking Global Investors, exiting entirely with an estimated $13.7M sold.

  • 100 institutional investors held Calithera Biosciences, Inc (CALA) as of Q1 2018, down from 112 in Q4 2017.
  • Funds reported $142M of Calithera Biosciences, Inc stock for Q1 2018, down 31% quarter-over-quarter.
  • 13 funds opened new Calithera Biosciences, Inc positions in Q1 2018 and 23 closed out, a net change of -10 holders.
  • The largest Calithera Biosciences, Inc buyer in Q1 2018 was Federated Hermes, an estimated $11.1M added.
  • The largest Calithera Biosciences, Inc seller in Q1 2018 was Viking Global Investors, an estimated $13.7M sold.

Based on aggregated 13F filings for Q1 2018.